Table 3.

Clinical Description and Outcomes of Patients Still in the ICU at Days 5–7 After Admission

Variables	Overall, N = 123	Immune Status Defined by Monocyte Expression of Human Leukocyte Antigen-DR			Immune Status Defined by Immune Profiling Panel
		Immunocompetent, N = 52 (42%)	Immunosuppressed, N = 71 (58%)	p	Immunocompetent, N = 55 (44%)	Immunosuppressed, N = 68 (56%)	p
Mechanical ventilation D30 FD	n = 80 26 (20–29)	n = 26 28 (26–29)	n = 54 25 (8–28)	0.004	n = 27 28 (26–29)	n = 53 25 (12–28)	0.005
ICU D28 FD	18 (12–20)	20 (17–21)	14 (6–19)	< 0.001	20 (18–21)	14 (4–19)	< 0.001
Hospital D28 FD	0 (0–9)	7 (0–14)	0 (0–4)	< 0.001	8 (0–13)	0 (0–3)	< 0.001
D28 death	8 (6.5)	0 (0)	8 (11)	0.020	1 (1.8)	7 (10)	0.074
D30 ICU-acquired infection	21 (17)	5 (9.6)	16 (22)	0.088	3 (5.4)	18 (26)	0.003

FD = free day.

Variables are described in all patients (overall) and in immune status groups defined by monocyte expression of human leukocyte antigen-DR (mHLA-DR) or by immune profiling panel (IPP). Categorical variables are expressed as n (%) and continuous variables as median (interquartile range). Comparisons between immune status groups defined by mHLA-DR or by IPP were performed with χ₂ or Fisher exact tests for qualitative variables and Mann-Whitney tests for quantitative variables, as appropriate. Values in bold indicate significance at p < 0.05. mHLA-DR and IPP measurements were censored at the occurrence of ICU-acquired infection.